menu
    • menu
    [{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Protein Sciences Corporation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Diamyd enters agreement to facilitate transition of manufacturing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Diamyd","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Protein Sciences Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Med.."}]

    Find Clinical Drug Pipeline Developments & Deals for Diamyd

    Menu

    Diamyd

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Diamyd Medical AB

                            Sweden arrow
                            BioProcess International
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diamyd

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Protein Sciences Corporation

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Diamyd enters agreement to facilitate transition of manufacturing

                            Details : The agreement facilitates the transition of the manufacturing process of recombinant GAD65, to a new manufacturer for future anticipated commercial manufacture.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : $5.0 million

                            February 05, 2020

                            Lead Product(s) : Diamyd

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Protein Sciences Corporation

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth